The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.
The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...
The US regulator expects to issue a decision on Eisai's application for Leqembi Iqlik, which it has granted priority review, by May 24.
Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
PRNewswire/ -- (Middletown, Delaware) a leading provider of high-value, system-critical elastomer components, announced a ...
Drug delivery utilizes various methods and/or carriers to transport therapeutic agents to the tissue, organ, cell, or subcellular organ of interest for release and absorption. Some of the primary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results